Reported about 12 hours ago
Novo Nordisk shares are struggling to recover from a 40% decline over the past six months, despite a recent boost from promising trial results for a weight-loss injection. Investors remain cautious ahead of upcoming earnings reports, particularly following disappointing outcomes for another drug. While analysts predict challenges ahead, some believe the stock is undervalued and may rebound as the company navigates its drug pipeline and market competition.
Source: YAHOO